
TREATMENTS
Exploring new frontiers for the treatment of Cerebrovascular Accident (Stroke)
TREATMENTS
Exploring new frontiers for the treatment of Cerebrovascular Accident (Stroke)
17+ Years of using patented and proven stem cell treatment for Cerebrovascular Accident (Stroke)
Cerebrovascular Accident (CVA) or Stroke as it is commonly called, occurs when the blood flow to the brain is impaired due to a blockage (Ischemic Stroke) or rupture (Hemorrhagic Stroke) of an artery to the brain. The lack of blood flow and the resulting lack of oxygen causes the death of the brain cells in the affected area. While a stroke occurring in the brain stem can affect both sides of the body, most strokes cause partial or complete paralysis of one side of the body. Problems with speech, vision and sensation can also occur.
Immediately after a stroke, conventional treatments are given to stabilize the patient, and to manage blood pressure, blood clotting/clots, blood sugar and oxygenation levels in the body. Once the acute phase is over and the patient is stable, rehabilitative therapies like physiotherapy, occupational therapy, speech therapy, etc. are introduced with the aim of increasing the functional abilities of the patient. However, these offer only limited gains as they do not address the underlying problem ie. the damaged brain cells. Regenerative therapy using stem cells is increasingly becoming the preferred treatment modality for stroke patients.
Stem cells have the potential to repair and regenerate the damaged and non-functional brain cells in stroke patients. It has shown improvements in motor & sensory function, speech, balance and coordination in stroke patients.
At Nutech MediWorld, we assess the patients’ clinical condition using conventional tools like the CT, MRI, etc. to check their eligibility for stem cell treatment for Cerebrovascular Accident (Stroke).
We also conduct an additional round of thorough assessment using our proprietary NFS (Nutech Functional System) protocols wherein condition-based parameters are used for a finer assessment of the patient’s condition (and progress).
After evaluating the patient’s condition, a customized treatment protocol is created for the patient. This protocol is based on our proprietary stem cell platform, ReoStem®.
.
The patient’s progress is monitored on a weekly basis to further optimize treatment protocols depending on the patient’s response.
At the end of the treatment period, a complete assessment is done to track progress from when the patient came in to where he/she has reached. If required, a follow-up treatment protocol is recommended.
At Nutech MediWorld, we follow an evidence-based, non-invasive, multi-disciplinary approach using Stem Cell Treatment & supporting therapies to improve the condition and overall quality of life for Cerebrovascular Accident (Stroke) patients. Each treatment protocol comprises of the use of our patented technology, customized to suit the condition of the individual patient.
At Nutech Mediworld, we follow an evidence-based, non-invasive, multi-disciplinary approach using Stem Cell Treatment & supporting therapies to improve the condition and overall quality of life for Cerebrovascular Accident (Stroke) patients. Each treatment protocol comprises of the use of our patented technology, customized to suit the condition of the individual patient
At Nutech Mediworld, we assess the patients’ clinical condition using conventional tools like the CT, MRI etc. to check their eligibility for stem cell treatment for Cerebrovascular Accident (Stroke)
We also conduct an additional round of thorough assessment using our proprietary NFS (Nutech Functional System) protocols wherein condition-based parameters are used for a finer assessment of the patient’s condition (and progress)
After evaluating the patient’s condition, a customized treatment protocol is created for the patient. This protocol is based on our proprietary stem cell platform, ReoStem
.
The patient’s progress is monitored on a weekly basis to further optimize treatment protocols depending on the patient’s response
At the end of the treatment period, a complete assessment is done to track progress from when the patient came in to where he/she has reached. If required, a follow-up treatment protocol is recommended
We use SCT-N® and SCT-NX® products, based on a proprietary stem cell platform, ReoStem®, which comprises of a unique, replicable, clinical-stage technology for the generation and clinical application of allogenic stem cells.
Nutech MediWorld’s regenerative medicine products are universally applicable: they do not require tissue-matching or the co-administration of immunosuppressive drugs.
There is no evidence of teratoma generation or tumorigenesis associated with SCT-N® or SCT-NX® use in over 17 years of clinical practice across thousands of patients.
The unique cell culture methodology allows scalability of cell expansion and production.